Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18507037 | 0.96 | HSD17B10 (0.48) | — | |
| SCHEMBL3955091 | 0.96 | — | — | |
| SCHEMBL7598 | 0.96 | — | — | |
| SCHEMBL20055722 | 0.92 | HSD17B10 (0.52) | — | |
| SCHEMBL463775 | 0.92 | HSD17B10 (0.52) | — | |
| Hydrochloric Acid SCHEMBL28431040 | 0.92 | — | — | |
| SCHEMBL2638 | 0.92 | — | — | |
| SCHEMBL1521924 | 0.92 | — | — | |
| SCHEMBL518261 | 0.92 | HSD17B10 (0.52) | — | |
| SCHEMBL60399 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116615417-B | 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-115919859-B | Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine | 四川海思科制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116615417-A | 1, 4-diheterocycle substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-115919859-A | Pharmaceutical composition of heteroaryl derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111471037-B | Allylamine compound and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-02-10 | — | — | CN | disclosed |
| CN-111434662-B | Haloallylamine compound and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | Integral Biosciences Privated Limited (IN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022224166-A1 | COMPOUNDS AS LXR AGONISTS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
| CN-115073449-A | Fused ring heterocyclic compound and application thereof, and pharmaceutical composition containing fused ring heterocyclic compound and application thereof | 浙江大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073448-A | Application of fused ring heterocyclic compound or pharmaceutically acceptable salt thereof in preparation of medicine for treating cerebral apoplexy | 浙江大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-105051005-B | Cyclopropylamine compound and use thereof | 武田药品工业株式会社 | 2017-06-13 | — | — | CN | disclosed |
| CN-106660955-A | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | 现代药品株式会社 | 2017-05-10 | — | — | CN | disclosed |
| WO-2016034134-A1 | HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-10 | — | — | WO | disclosed |
| CN-105051005-A | Cyclopropylamine compound and use thereof | TAKEDA PHARMACEUTICAL | 2015-11-11 | — | — | CN | disclosed |
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| CN-104334557-A | Diacylglycerol acyltransferase 2 inhibitors | PFIZER | 2015-02-04 | — | — | CN | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-0648769-A1 | 12-Hetero-substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1995-04-19 | — | — | EP | disclosed |
| US-5380729-A | Treatment or prevention of neurodegenerative disorders or neurotoxic injuries | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| US-4486608-A | Preparation of mono- and dibromo- or chloroaldehydes | THE DOW CHEMICAL COMPANY (US) | 1984-12-04 | — | — | US | disclosed |